Invasive pneumococcal disease in Scotland, 1999-2001: Use of record linkage to explore associations between patients and disease in relation to future vaccination policy

被引：59

作者：

Kyaw, MH

Christie, P

Clarke, SC

Mooney, JD

Ahmed, S

Jones, IG

Campbell, H

机构：

[1] Scottish Ctr Infect & Environm Hlth, Glasgow, Lanark, Scotland

[2] Scottish Meningococcus & Pneumococcus Reference L, Glasgow, Lanark, Scotland

[3] Univ Edinburgh, Edinburgh, Midlothian, Scotland

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 37卷 / 10期

关键词：

D O I：

10.1086/379016

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A record linkage study was done to provide comprehensive data on the epidemiologic characteristics of invasive pneumococcal disease (IPD) in Scotland. The overall incidence of IPD was 11 cases/10(5) persons and 21 cases/10(5) persons <1 year of age, 51 cases/10(5) persons 1 year of age, 45 cases/10(5) elderly persons (age ≥ 65 years), 176-483 cases/10(5) persons with chronic medical conditions, and 562-2031 cases/10(5) persons with severe immunosuppression. The case-fatality rate was 11% among elderly persons and ranged from 3% to 13% among persons with underlying medical conditions. The most common pneumococcal serogroups associated with IPD were 14, 9, 6, 19, 23, 8, and 4. Serogroups included in the 23-valent polysaccharide vaccine caused the majority of cases of IPD. The proportion of IPD due to the 7-, 9-, and 11-valent conjugate vaccine serogroups was lower among older people and persons with underlying medical conditions.

引用

页码：1283 / 1291

页数：9

共 29 条

[1] Cost-effectiveness of pneumococcal vaccination of older people:: A study in 5 western European countries [J].

Ament, A ;

Baltussen, R ;

Duru, G ;

Rigaud-Bully, C ;

de Graeve, D ;

Örtqvist, Å ;

Jönsson, B ;

Verhaegen, J ;

Gaillat, J ;

Christie, P ;

Cifre, AS ;

Vivas, D ;

Loiseau, C ;

Fedson, DS .

CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :444-450

[2] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].

Black, S ;

Shinefield, H ;

Fireman, B ;

Lewis, E ;

Ray, P ;

Hansen, JR ;

Elvin, L ;

Ensor, KM ;

Hackell, J ;

Siber, G ;

Malinoski, F ;

Madore, D ;

Chang, I ;

Kohberger, R ;

Watson, W ;

Austrian, R ;

Edwards, K .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195

[3] PNEUMOCOCCAL BACTEREMIA IN CHARLESTON COUNTY, SOUTH-CAROLINA - A DECADE LATER [J].

BREIMAN, RF ;

SPIKA, JS ;

NAVARRO, VJ ;

DARDEN, PM ;

DARBY, CP .

ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (07) :1401-1405

[4] PNEUMOCOCCAL POLYSACCHARIDE VACCINE EFFICACY - AN EVALUATION OF CURRENT RECOMMENDATIONS [J].

BUTLER, JC ;

BREIMAN, RF ;

CAMPBELL, JF ;

LIPMAN, HB ;

BROOME, CV ;

FACKLAM, RR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (15) :1826-1831

[5]

*CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1

[6]

Chen FM, 1998, AM J EPIDEMIOL, V148, P1212, DOI 10.1093/oxfordjournals.aje.a009611

[7]

Collignon PJ, 2000, MED J AUSTRALIA, V173, pS58

[8] Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees [J].

Dagan, R ;

Sikuler-Cohen, M ;

Zamir, O ;

Janco, J ;

Givon-Lavi, N ;

Fraser, D .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (10) :951-958

[9] Immunogenicity of pneumococcal conjugate vaccines [J].

Eskola, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (04) :388-393

[10]

FEDSON DS, 1999, VACCINES, P553

← 1 2 3 →